Investor Presentation Q1 2023
10
Investor presentation
First three months of 2023
Rare disease sales decreased by 16% driven by temporary
reduction in manufacturing output
Reported Rare disease sales
Rare disease sales driven by global commercial execution
Growth at CER
DKK
billion
5
-16%
-3%
19%
4
Rare disease sales decrease is driven by:
15%
-11%
-38%
•
14% sales decline in North America Operations
•
17% sales decline in International Operations
3
Rare blood disorders
2
1
0
Total1
Rare
blood
Haem.
A
Haem.
B
Novo- !
SevenⓇ
disorders²
Rare
endocrine
disorders³
.
.
Rare blood disorders sales decreased by 3%, driven by:
Lower sales of NovoSevenⓇ partially countered by sales of
haemophilia A and B products
Rare endocrine disorders sales decreased by 38% driven by:
North America Operations sales for Norditropin® declined by 33%
driven by temporary reduction in manufacturing output and lower
realised prices in the US
Novo Nordisk is the leading company in the global human growth
disorder market with a value market share of ~35%
¹Total includes "Other Rare disease", which consists of primarily Vagifem® and Activelle; 2Comprises NovoSeven®, Novo Eight®, Esperoct®, RefixiaⓇ and NovoThirteenⓇ; 3 Primarily NorditropinⓇ;
CER: Constant exchange rates; Haem. A: Haemophilia A; Haem. B: Haemophilia B; Unless otherwise specified, sales growth is at constant exchange rates
Note: NovoThirteenⓇ is not shown for Rare blood disorders breakdown, only for the total bar.
Novo NordiskⓇView entire presentation